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Abstract
Purpose
To analyze the clinical features and prognostic factors associated with the survival of patients
with a very rare occurrence of brain metastasis (BM) from differentiated thyroid cancer (DTC).
Methods and Materials
A total of 37 patients with DTC who were diagnosed with BM between 1995 and 2014 were
included. We reviewed the clinical characteristics, treatment modalities, and image findings
of BM. Factors associated with survival were evaluated, and the patients were divided into
three prognostic groups (Groups A, B, and C) for comparative analysis.
Results
The median age at BM was 63 years, and the median time from initial thyroid cancer diagno-
sis to BM was 3.8 years. The median survival and the 1-year actuarial survival rate after BM
were 8.8 months and 47%, respectively. According to univariate and multivariate analyses,
four good prognostic factors (GPFs) were identified including age 60 years, PS ECOG
2, 3 BM sites, and without extracranial metastasis prior to BM. Three prognostic groups
were designed based on age and number of remaining GPFs: patients 60 years of age
with at least 2 GPFs (Group A) had the most favorable prognosis with a median survival of
32.8 months; patients 60 years of age with fewer than 2 GPFs and those > 60 years of
age with at least 2 GPFs (Group B) had an intermediate prognosis with a median survival of
9.4 months; and patients > 60 years of age with fewer than 2 GPFs (Group C) had the least
favorable prognosis with a median survival of 1.5 months.
Conclusions
The survival of patients with BM form DTC differed among the prognostic groups based on
the total number of good prognostic factors.
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Introduction
Carcinoma of the thyroid gland is the most common cancer, accounting for 16.6% of all newly
diagnosed cancers in Korea [1]. The incidence of thyroid cancer is increasing worldwide, par-
ticularly because of a rise in papillary thyroid cancer, the most common form of thyroid cancer.
The prognosis of thyroid cancer is related to the histology subtype and the stage at the time of
diagnosis. Thyroid cancer is usually indolent with good prognosis and long-term survival, even
with its high incidence of distant metastases [2–4]. The overall incidence of distant metastases
varies between 10% and 35%, depending upon the histology [3].
The major sites of distant metastases from thyroid cancer are the lung (70%) and bone
(20%), and multiple sites are involved in 10–20% of patients at the time of diagnosis [5].
Although patients with M1 thyroid cancer might live for a prolonged period with the disease,
the presence of distant metastasis has a significant impact on patient survival [6]. Meanwhile,
thyroid cancer represents a brain metastasis (BM) from approximately 1% of all differentiated
thyroid cancer (DTC) to around 10% of anaplastic patients. The reported median survival of
patients diagnosed with BM varies between 4 months and 33 months [5, 7, 8]. Because of its
rarity, the impact of BM on the survival of patients with DTC is unknown, and there are no
clear guidelines for managing patients with BM from DTC. For BM in general, although treat-
ment guidelines can differ based on the prognosis of the patients and the extent of the BM, sur-
gery remains the preferred treatment modality [9]. With the indolent course and rarity of BM
from DTC, however, more information on treatment outcomes is needed to support the stan-
dard guidelines for BMmanagement.
In this study, we report the clinical features and potential prognostic factors associated with
the survival of patients with a very rare occurrence BM from DTC.
Materials and Methods
Patients
Between 1995 and 2014, a total of 37 histologically confirmed DTC patients were diagnosed
with BM at out institution. This Institutional Review Board of the Severance Hospital, Korea
(IRB No. 3-2015-0134) approved this retrospective study in accordance with ethical guide-
lines and the Declaration of Helsinki. The consent was not necessary, because patient records
and information were anonymized and de-identified prior to analysis. We retrospectively
reviewed the medical records of the patients, including the clinical presentation, treatment
received, radiologic features of BM, and clinical course. All of the reviewed patients had
undergone surgery for primary thyroid cancer, and the pathology was confirmed. When BM
was clinically suspected, the patients underwent computed tomography (CT) scans or mag-
netic resonance imaging (MRI) to confirm the diagnosis of BM. We examined the following
clinical factors for association with survival: age, sex, time interval between initial thyroid
cancer diagnosis and BM, Eastern Cooperative Oncology Group (ECOG) performance status
(PS), presenting symptoms of BM, treatment modality for BM, number of brain lesions,
tumor size, extracranial metastases diagnosed prior to BM (present or absent), and primary
thyroid cancer recurrence. Among them, factors showed a statistically potential association
with survival defined as good prognostic factors (GPFs). Based on these factors, we divided
the patients into three prognostic groups according to the total number of potential prognos-
tic factors established in the analysis. Survival curves among the prognostic groups (Groups
A, B, and C) were compared. In cases of radiosurgery, both Gamma Knife and linear acceler-
ator-based therapies were included.
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Statistical analysis
Overall survival was defined from the date of BM diagnosis to the date of the last follow-up or
death. Survival data were analyzed using the Kaplan-Meier method. The number of BM lesions
was counted on imaging. The tumor size was measured as the longest diameter of the largest
intracranial tumor regardless of the number and location of the brain lesions. A univariate
analysis was performed using the log-rank test to identify prognostic factors associated with
survival, and multivariate analyses were performed using the Cox proportional hazards model.
Statistical analysis was carried out using SPSS version 20 (SPSS Inc., Chicago, USA). P
values 0.05 were considered statistically significant.
Results
Patient and tumor characteristics
The characteristics of the patients and tumors are presented in Table 1. The median age of the
patients was 59 (range, 29–76) years at initial diagnosis of thyroid cancer and 63 (range, 39–78)
years at BM diagnosis. The median time interval from diagnosis of thyroid cancer to BM develop-
ment was 3.8 (range, 0–30.7) years. Twenty-one patients were female, and 16 patients were male.
The histological subtypes were 32 papillary thyroid carcinoma, 3 follicular carcinoma, and 2
poorly differentiated carcinoma. The ECOG PS at BM diagnosis was 0–1 (16 patients), 2 (14
patients), or 3 (7 patients). Twenty-five patients were diagnosed with BM based on neurologic
symptoms including headache, nausea, mental change, ataxia, and motor or sensory deficits, and
12 patients without symptoms were diagnosed with BM incidentally during evaluation for their
initial or synchronous multiple distant metastases. The most common symptoms were motor def-
icits followed by headache and dizziness. The site of first presentation of distant metastasis was
the lung for 25 patients and the brain for 13 patients, and 4 patients had both lung and brain
metastases simultaneously. The median interval between initial lung metastasis and subsequent
BM was 12.9 months. At the time of BM diagnosis, 21 patients had recurrent primary thyroid
tumors, and 24 patients had previously diagnosed extracranial metastases.
Radiologic findings of BM and treatment profiles
All of the patients performed CT (51.3%), MRI (89.2%), or both (40.5%) for BM diagnosis. The
study included 9 patients with 1 BM site, 12 patients had 2 or 3 BM sites, 11 patients had from
4 to 9 BM sites, and 5 patients had more than 10 BM sites. The mean value of maximum meta-
static tumor diameter was 2.1 cm.
Metastases were treated by surgical resection alone in 3 patients (1–5 lesions), radiosurgery
alone in 8 patients (1 lesions), partial-brain radiotherapy (PBRT) in 6 patients (1–4 lesions) and
whole-brain RT (WBRT) in 6 patients (3 lesions). Three patients underwent resection followed
byWBRT for 1–4 lesions, and one patient underwent resection followed by PBRT for a single
lesion. Three patients received radiosurgery combined with RT: two underwent WBRT, and one
underwent PBRT after post-radiosurgery progression. Seven patients including one who received
chemotherapy were managed with conservative care without surgery or RT. Among the 19
patients who received RT, 9 underwent PBRT, and 10 underwent WBRT. The RT schedule was
37.5–71.25 Gy in 10–30 fractions for PBRT and 25–40 Gy in 8–15 fractions forWBRT. Most of
the radiosurgery was performed by Gamma Knife with a maximal dose of 30 Gy.
Survival and prognostic subgroups
The median survival after BM was 8.8 (range, 0.7–109) months. The overall survival at 1 year
and 2 years was 47% and 30.2%, respectively. The median survival was 16.7 months for the
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BM-treatment group (n = 30) and 2.6 months for the non-treatment group (n = 7; p< 0.001).
In the univariate analysis, four factors showed a significant association with survival. Age had a
strong impact on survival; the median overall survival was 32.8 months for patients 60 years
of age versus 8.8 months for patients> 60 years of age (p = 0.002). Patients with PS ECOG 2
had a median survival of 16.7 months, whereas patients with PS> ECOG 2 had a median sur-
vival of 1.6 months (p< 0.001). The median survival of patients with 1–3 BM sites was 30.7
months, whereas that of patients with more than 3 BM sites was only 8.8 months (p = 0.004).
With respect to the treatment modality, the median survival was better for patients who under-
went either surgical resection or radiosurgery (30.7 months) compared with that for patients
who did not undergo those treatment modalities (5 months; p = 0.001). The median survival
Table 1. Clinical characteristics of the 37 patients with brain metastasis from thyroid cancer.
Characteristics No. of patients (%)
Age at diagnosis of brain metastasis (years)
Median (range) 63 (39–78)
Time from diagnosis of thyroid cancer to BM (years)
Median (range) 3.8 (0–30.7)
Sex
Male 16 (43.2)
Female 21 (56.8)
Histology
Papillary 32 (86.5)
Follicular 3 (8.1)
Poorly differentiated 2 (5.4)
Performance status
ECOG 0–1 16 (43.2)
ECOG 2 14 (37.8)
ECOG 3 7 (18.9)
Symptoms
Sensory deficit 1 (2.7)
Motor deficit 8 (21.6)
Headache 4 (10.8)
Nausea/vomiting 2 (5.4)
Mental change 3 (8.1)
Ataxia 2 (5.4)
Dizziness 4 (10.8)
Memory loss 1 (2.7)
None 12 (32.4)
Number of BM sites
1–3 21 (56.8)
4–9 11 (29.7)
 10 5 (13.5)
Site of initial distant metastasis
Lung 25 (67.6)
Brain 13 (35.1)
Lymph node 2 (5.4)
Bone 4 (10.8)
Spine 5 (13.5)
Other 3 (8.1)
doi:10.1371/journal.pone.0154739.t001
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among patients with extracranial metastases prior to BM diagnosis (10 months) was worse
than that among patients without prior extracranial metastases (19.2 months; p = 0.065).
There was no statistically significant effect on survival of sex, time interval between initial thy-
roid cancer diagnosis and BM diagnosis, presence of neurologic symptoms, history of radio-
therapy (RT), or primary site recurrence. The age (HR = 9.146, p = 0.004), PS (HR = 4.449,
p = 0.031), number of BM sites (HR = 3.455, p = 0.016), and extracranial metastasis prior to
BM (HR = 4.829, p = 0.005) were independent prognostic factors for survival in the multivari-
ate analyses. According to these results, four GPFs were identified including age 60 years,
PS ECOG 2, 3 BM sites, and without extracranial metastasis prior to BM. The results of
the univariate and multivariate analyses are summarized in Table 2.
Based on the independent prognostic factors excluding treatment modality (surgery or
radiosurgery), the patients were divided into 3 prognostic groups: patients 60 years of age
Table 2. Univariate andmultivariate analysis of predictors associated with survival in patients with brain metastasis from thyroid cancer.
variable n Univariate Multivariate
median (mon) 95% CI p HR p
Age (years) 0.002 0.004
 60 15 32.8 5.5–60 Ref.
> 60 22 8.8 5.4–12.1 9.146
Sex 0.266
Male 16 19.2 8.1–30.2
Female 21 10 7.7–12.2
Time interval (years) 0.634
 3 18 10 7.7–12.2
> 3 19 19.4 4.3–34.4
ECOG PS <0.001 0.031
 2 30 16.7 6.6–26.8 Ref.
> 3 7 1.6 0.0–3.2 4.449
Neurologic symptoms 0.571
Yes 25 11.5 5.1–17.8
No 12 11.7 0.0–25.9
Radiotherapy 0.901
Yes 19 11.7 3.3–20.0
No 18 11.5 3.7–19.2
OP or SRS 0.001 0.092
Yes 18 30.7 3.0–58.3 Ref.
No 19 5 0.0–11.3 2.658
Number of BM sites 0.004 0.016
 3 21 30.7 8.8–52.5 Ref.
> 3 16 8.8 2.2–15.3 3.455
Prior DM 0.065 0.005
Yes 24 10 5.4–14.5 4.829
No 13 19.2 6.9–31.4 Ref.
Primary site recurrence 0.248
Yes 21 11.5 6.6–16.3
No 16 11.7 2.6–20.7 　 　 　
Abbreviations: PS = performance status; OP = operation; SRS = stereotactic radiosurgery; BM = brain metastasis; DM = distant metastasis
doi:10.1371/journal.pone.0154739.t002
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with at least 2 GPFs (Group A); patients 60 years of age with fewer than 2 GPFs and
those> 60 years of age with at least 2 GPFs (Group B); and patients> 60 years of age with
fewer than 2 GPFs (Group C). As shown in Table 3, the survival rates differed significantly
among the prognostic groups. Group A (n = 9) had a median survival of 32.8 months and a
1-year survival rate of 87.5%, while Group C (n = 10), the least favorable group, had a median
survival of only 1.5 months and 1-year survival rate of 0%. Group B (n = 18), the intermediate
group, had a median survival of 9.4 months and a 1-year survival rate of 48.1%. The survival
curves of the three prognostic groups are compared in Fig 1.
Treatment patterns and causes of death among the subgroups
The features and outcomes of the nine patients in Group A are described in Table 4. Among
those patients, seven received either surgical resection or radiosurgery, and the remaining two
received RT alone. The patient with the most favorable outcome had all of the GPF and was
treated with radiosurgery for a single BM lesion. No evidence of further disease progression
was found in that patient during the last follow-up. Three patients in Group A had only short-
term survival (11.2, 6.4, and 8.9 months), however, resulting from follow-up loss or the treat-
ment of multiple BM. No patient in Group A died from a brain progression. On the other
hand, 5 of the 10 patients in Group C were managed only with conservative treatment, and 3 of
those patients died due to brain progression.
Discussion
Several studies have investigated the treatment outcomes of BM from primary cancers includ-
ing lung, breast, and colorectal cancers and melanoma. In breast cancer, the second most fre-
quent cause of BM, the BM typically occurs in the late stages of metastatic breast cancer. In one
study, the median overall survival after BM from breast cancer was 11.5 months, and while the
treatment outcome differed among cancer subtypes (ER, PR, Her2 status), focal brain treat-
ment could be considered for better local control of BM in patients with aggressive subtypes
[10]. BM from hepatocellular carcinoma (HCC) is frequently associated with intracranial hem-
orrhage, because HCC is hypervascular, and most patients have coagulopathy. Although the
overall prognosis for patients with BM from HCC is extremely poor with median survival of
only 6.8 weeks, some subsets of patients manifest favorable survival criteria including single
brain metastasis and good liver function [11].
The clinical courses and outcomes of BM from thyroid cancer are unclear, because the prev-
alence of BM from DTC is rare. In this study, we investigated the clinical features and prognos-
tic factors of 37 patients with BM from DTC. The most frequent site of first distant metastasis
was the lung followed by the brain. Most of the patients died with lung progression, although
the patients who were treated for BM had a better survival compared to those who were not.
Table 3. Comparison of overall survival rates among prognostic subgroups.
Prognostic subgroup
Group A (n = 9) Group B (n = 18) Group C (n = 10)
Definition Age  60 & GPF  2 Age  60 & GPF < 2 or Age > 60 & GPF  2 Age > 60 & GPF < 2
Survival rates
Median (months) 32.8 9.4 1.5
1-year (%) 87.5 48.1 0
Abbreviations: GPF = good prognostic factor, including performance status  ECOG 2,  3 BM sites, and without extracranial metastasis prior to BM
doi:10.1371/journal.pone.0154739.t003
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Also, considering that the median time interval from the initial diagnosis of thyroid cancer to
the diagnosis of BM was 3.8 years, both the BM and the primary cancer follow an indolent
course, suggesting that aggressive treatment of both intracranial and extracranial metastases is
needed for longer survival. Although BM tended to be identified more commonly in patients
with aggressive histologic types, BM originating from poorly differentiated thyroid carcinoma
was extremely rare in this study. It is in line with previously published reports that included
mostly patients with DTC. [5, 12–14]
The management of BM from DTC remains undetermined because of a paucity of recent
data, and most of the published reports are based on data from old series with symptomatic
patients [5]. It is widely thought that chemotherapy is seldom helpful for most type of thyroid
cancer and distant metastasis from thyroid cancer, which may support the non-chemotherapy
treatments of BM implemented in this study. General treatment guidelines can be differenti-
ated based on the prognosis of the patients and the extent of the BM disease [10]. Maximal
Fig 1. Overall survival comparison among the three prognostic subgroups.Group A: patients 60 years of age and at
least 2 good prognostic factors (GPF); Group B: patients 60 years of age and fewer than 2 GPF or > 60 years of age with at
least 2 GPF; Group C: patients > 60 years of age and fewer than 2 GPF.
doi:10.1371/journal.pone.0154739.g001
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surgical resection followed by stereotactic radiosurgery (SRS) or WBRT results in better sur-
vival rates compared with WBRT alone [15, 16]. The use of radiosurgery is increasing for the
treatment of a limited number of brain metastases. SRS alone or in addition to WBRT has been
shown to achieve excellent local control rates and patient functional status [17]. Therefore, sur-
gical resection or radiosurgery might have been performed in patients with one or a limited
number of BM lesions, an absent or a controlled systemic disease, a life expectancy 3
months, and a good PS [18, 19]. For decades, WBRT has been the standard treatment for
patients with multiple lesions, a life expectancy< 3 months, or a low Karnofsky Performance
Status (KPS) score [18, 19]. Those guidelines are not specific, however, to patients with thyroid
cancer. In this study, the median survival after BM was 8.8 months, but the patients who were
treated with surgery or radiosurgery had a median survival of 30.7 months compared with only
5 months for those who did not receive surgery or radiosurgery. Chie et al. [20] reported that
among 36 patients with BM from thyroid cancer, those who received surgery or SRS had a
median survival of 16.7 months, whereas those who did not receive those treatments had a
median survival of 4.7 months. Another single-institutional study showed that overall survival
among patients who received surgery or SRS was 37.4 months compared with 20.8 months
among patients who did not receive those treatments [21]. Unfortunately, we could not find
the effect of even local RT on patient survival in our study.
We believe that this study is the largest among the published reports evaluating the treat-
ment outcomes of BM from DTC. We evaluated the treatment outcomes based on three prog-
nostic groups. Prognostic factors that help predict patient survival are important for making
treatment decisions for individual patients. There are at present several prognostic indices to
guide treatment decisions for patients with BM [22–24]. The Radiation Therapy Oncology
Group (RTOG) recursive partitioning analysis (RPA) [22], which is the index most commonly
used to evaluate BM prognosis, includes 3 classes: Class I includes patients< 65 years of age
with KPS 70, controlled primary tumor, and no extracranial metastases; Class III includes
patients with KPS< 70; and Class II includes all patients not in Classes I or III. In order to
Table 4. Features and outcomes of nine patients belonging to Group A.
Patient Sex Age at
BM
(years)
Histology Time
interval
from TC to
BM (years)
Performance
status
(ECOG)
Number
of BM
Neurologic
symptoms
Treatment
for BM
Extracranial
metastasis
Current
status
OS
(months)
1 M 58 papillary 7.6 2 1 motor deficit Op+3D-CRT lung AWD 11.2
2 F 50 papillary 10.2 1 2 headache IMRT lung AWD 6.4
3 M 50 papillary 4.1 1 2 none Radiosurgery lung DOD 40.7
4 F 50 papillary 3.8 1 3 headache,
nausea
Radiosurgery lung DOD 32.8
5 M 50 papillary 4.1 1 2 none Radiosurgery none DOD 41.1
6 F 55 papillary synchronous 2 10 motor deficit Radiosurgery
+WBRT
none DOD 8.9
7 M 42 papillary synchronous 0 1 none Radiosurgery none NED 109
8 F 54 follicular synchronous 1 1 ataxia,
headache
Op+WBRT none AWD 58.5
9 M 49 follicular synchronous 2 1 headache,
dizziness
IMRT none AWD 26.9
Abbreviations: BM = brain metastasis; TC = thyroid cancer; DM = distant metastasis; OS = overall survival; OP = operation; CRT = conformal
radiotherapy; IMRT = intensity modulated radiotherapy; WBRT = whole-brain RT; AWD = alive with disease; DOD = death of disease; NED = no evidence
of disease
doi:10.1371/journal.pone.0154739.t004
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incorporate the number of metastases and eliminate treatment factors for the guidance of treat-
ment choice, the Graded Prognostic Assessment [25] was developed, which sums up the scores
(0, 0.5, and 1.0) for each of the 4 prognostic factors (age, KPS, extracranial metastases, and
number of central nervous system metastases). Despite the fact that those indices were derived
through the analysis of many possible prognostic factors, the biological behaviors of various
primary tumors can be quite different, making it difficult to apply one common index to all
types of BM. Rades et al. [26] included independent predictors of survival (gender, KPS, and
extracranial metastases) in a scoring system for BM from non-small cell lung cancer, in which
the score for each of the factors was obtained from the 6-month survival rate divided by 10.
The survival rate was very different among the three prognostic groups defined based on the
total score, providing a tool to help offer the best available treatment to each patient. With
respect to thyroid cancer prognosis, which is related to the histologic type, the treatment out-
comes for patients with BM could differ from those for patients with other primary cancers.
Furthermore, we found that BM from thyroid cancer had a radioresistant feature, so survival
estimation could help determine the appropriate treatment. Consequently, it seems useful to
group patients with BM from thyroid cancer according to their expected survival. Because age
was the strongest prognostic factor for both BM and primary thyroid cancer, three prognostic
groups were designed based on a number of other prognostic factors including PS, number of
BM sites, and distant metastasis prior to DM diagnosis. Patients in Group A had the most
favorable prognosis with a median survival of 32.8 months. Meanwhile, patients in Group B
had an intermediate prognosis with a median survival of 9.4 months, and patients in Group C
had the least favorable prognosis with a median survival of only 1.5 months. The survival was
thus very different among the three groups. Based on those group classifications, we can esti-
mate the expected survival of patients with BM from DTC before we treat the BM. We found
that some specific groups of patients could expect long-term survival over 30 months as a result
of appropriate treatment. Although this study reflects the treatment results of only a small
group of patients, we can expect improved outcomes with surgical resection or radiosurgery,
especially for patients classified in Group A with oligometastases of brain.
This study was a retrospective review of previously collected data, and there might have
been a selection bias with respect to the treatment modality received, because the patients who
received either surgery or radiosurgery were very specifically selected. The majority of the
patients who received WBRT underwent only palliative treatment for multiple BMs and had a
poor PS, the factors that had little impact on survival. In addition, the prognostic subgroups
defined in the current study have not been validated in a prospective study, which is not likely
to be expected because of the rare incidence of BM from DTC.
Conclusion
The results of this retrospective study show that clinical features such as age ( 60 years), PS
( 2), number of BM sites ( 3), and absence of previous distant metastasis prior to BM devel-
opment were independently associated with survival. Survival differed among the prognostic
groups based on those clinical features. Therefore, we can estimate the survival of patients with
BM from DTC based on those prognostic factors and recommend more definitive treatment
such as surgery or radiosurgery for long-term survival in patients with GPF.
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